Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.

CEO

ISIN

US00887A2042

Listings

0 Comments

Share your thoughts

FAQ

What is Rein Therapeutics stock price today?▼

The current price of RNTX.BOATS is $1.31 USD — it has increased by +0% in the past 24 hours. Watch Rein Therapeutics stock price performance more closely on the chart.

What is Rein Therapeutics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Rein Therapeutics stocks are traded under the ticker RNTX.BOATS.

What is Rein Therapeutics market cap?▼

Today Rein Therapeutics has the market capitalization of 34.43M

When is the next Rein Therapeutics earnings date?▼

Rein Therapeutics is going to release the next earnings report on May 20, 2026.

What is Rein Therapeutics revenue for the last year?▼

Rein Therapeutics revenue for the last year amounts to 0 USD.

What is Rein Therapeutics net income for the last year?▼

RNTX.BOATS net income for the last year is -125.77M USD.

When did Rein Therapeutics complete a stock split?▼

Rein Therapeutics has not had any recent stock splits.